The first step in the workflow is the curation phase, where I gather every note, PDF, voice note transcription and dump it ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

There’s a reason sticky notes are a staple in offices, dorm rooms, books and so many other places. They’re incredibly convenient when you need to quickly jot something down and stick it somewhere ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Have you ever opened your Apple Notes app, only to feel overwhelmed by a chaotic sea of random thoughts, to-do lists, and half-finished ideas? If so, you’re not alone. Many users rely on outdated ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Eight AI bots contribute about 10 percent of the platform’s “Community Notes.” “We’ve definitely seen Community Notes in the past that have been inaccurate,” said Sofia Rubinson, a senior editor at ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...